Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks of and Mozobil(TM) and Synvisc-ONE(TM) are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Conference Call Information

Genzyme will host a conference call today at 11:00 a.m. Eastern to discuss results for the first quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and th
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... “2014 Deep Research Report ... is a professional and in-depth research report ... Polyurethane Resin basic information, including its definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
(Date:7/31/2014)... even the entire body to visualize long-range connections between ... a long-time dream of biologists. A study published by ... Cell has now made that dream a ... and human tissue biopsies transparent, while keeping the cellular ... way for a better understanding of brain-body interactions, more ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, a ... Bay Area , has acquired a licence to ... commercialisation company. The potent anti-inflammatory activity of the peptides ... the University of Oxford,s Sir William Dunn School ... has raised over $1.5 million in seed financing, is ...
(Date:7/31/2014)... San Francisco, California (PRWEB) July 31, 2014 ... expert systems that inform therapeutic decision-making in oncology, today ... on August 14, 2014 to discuss the Company's financial ... to provide an update about the business in the ... live audio call beginning on Thursday, August 14, 2014, ...
Breaking Biology Technology:Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... Spherix Incorporated,(Nasdaq: SPEX ) reported that the ... listing of its common stock from the Nasdaq,Global Market ... expected to,commence trading on the Nasdaq Capital Market on ... one of three market tier designations for,Nasdaq-listed stocks, and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) announced today ... Sept. 30, 2008., Third Quarter and Nine Months ... nine months ended Sept. 30, 2008, was,$3.8 million and ... respectively in 2007. Revenue in the third quarter and ...
... ... Performance - ... PLYMOUTH MEETING, Pa., Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... the third quarter ended September,30, 2008. During the quarter, BMP Sunstone successfully ...
Cached Biology Technology:Spherix Transfers Stock Listing to Nasdaq Capital Market 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6BMP Sunstone Reports Third Quarter 2008 Financial Results 2BMP Sunstone Reports Third Quarter 2008 Financial Results 3BMP Sunstone Reports Third Quarter 2008 Financial Results 4BMP Sunstone Reports Third Quarter 2008 Financial Results 5BMP Sunstone Reports Third Quarter 2008 Financial Results 6BMP Sunstone Reports Third Quarter 2008 Financial Results 7BMP Sunstone Reports Third Quarter 2008 Financial Results 8BMP Sunstone Reports Third Quarter 2008 Financial Results 9BMP Sunstone Reports Third Quarter 2008 Financial Results 10BMP Sunstone Reports Third Quarter 2008 Financial Results 11BMP Sunstone Reports Third Quarter 2008 Financial Results 12BMP Sunstone Reports Third Quarter 2008 Financial Results 13BMP Sunstone Reports Third Quarter 2008 Financial Results 14
(Date:7/31/2014)... follow-up study (HPV-023; NCT00518336) shows the sustained ... papilloma virus (HPV) vaccine Cervarix. Women vaccinated ... for more than nine years, and vaccine ... This is the longest follow-up report for ... for the full paper. , ...
(Date:7/31/2014)... 100 percent of animal models against the highly infectious ... an intestinal disease that kills approximately 30,000 Americans annually. ... Infection and Immunity . , In the study, ... the purified toxins produced by C. difficile , ... laboratory model that mimics the human disease, after only ...
(Date:7/31/2014)... Mont. In the same week that the U.S. ... of skin cancer, researchers at Montana State University published ... the genetic code in every cell responds when ... fundamental understanding of DNA damage by the UV rays ... cancer, aging and some degenerative eye diseases. , ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... more today than ever before about the microbes that inhabit ... gathering all of the relevant bits of information into one ... Now, grantees of the National Institute of Dental and ... and their international colleagues intend to solve this problem with ...
... investigating a radical new design for cargo ships that ... non-native creatures to sneak into the Great Lakes from ... been identified in the Great Lakes, and ballast water ... zebra and quagga mussels and two species of gobies. ...
... dispositions of strangers by observing others behavior and ... ability to recognize certain behavioral traits and make ... traits in strangers in similar situations thereafter. These ... George Washington University in Washington DC - and ...
Cached Biology News:Scientists launch first comprehensive database of human oral microbiome 2Scientists launch first comprehensive database of human oral microbiome 3U-M 'ballast-free ship' could cut costs while blocking aquatic invaders 2U-M 'ballast-free ship' could cut costs while blocking aquatic invaders 3Who's bad? Chimps figure it out by observation 2
... is a compact analysis system for the clinical ... a controller, advanced digital signal processing and a ... system includes the Luminex 100, the XY Platform, ... file at the FDA, and partner kits that ...
... nutritious peptone, used in ... of bacterial toxins, and ... bacteria with high nutritional ... Neisseria, Pasteurella, Salmonella and ...
... Ham's F12K medium with 2 mM L-glutamine and ... order to keep the antigens in their native ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
Biology Products: